Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies

Clinical Therapeutics

Volumn 28, Issue 11, 2006, Pages 1779-1802

  Shih, Ted ^a   Lindley, Celeste ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

angiogenesis; bevacizumab; breast cancer; colorectal cancer; non small cell lung cancer; renal cell carcinoma; vascular endothelial growth factor

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANGIOGENESIS INHIBITOR; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CALCIUM CHANNEL BLOCKING AGENT; CAPECITABINE; CARBOPLATIN; CETUXIMAB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOCETAXEL; DOXORUBICIN; ENDOTHELIAL CELL GROWTH FACTOR; ERLOTINIB; ESTRAMUSTINE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; NAVELBINE; OXALIPLATIN; PACLITAXEL;

ADJUVANT THERAPY; AGE DISTRIBUTION; ANGIOGENESIS; ARTERY THROMBOSIS; BLEEDING; BODY WEIGHT; BREAST CANCER; CANCER SURVIVAL; CARDIOTOXICITY; CHILL; CLINICAL TRIAL; COLON DIVERTICULOSIS; COLORECTAL CANCER; DEATH; DEEP VEIN THROMBOSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE MARKER; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; FEVER; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HEADACHE; HEART INFARCTION; HEMATOLOGIC DISEASE; HEMATURIA; HEMOPTYSIS; HUMAN; HYPERTENSION; INFECTION; INTESTINE PERFORATION; KIDNEY CARCINOMA; KIDNEY FUNCTION; LEUKOPENIA; LINEAR SYSTEM; LITERATURE; LOW DRUG DOSE; LUNG EMBOLISM; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MEDLINE; MESENTERIC VEIN THROMBOSIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEPHROTIC SYNDROME; NEUTROPENIA; PANCREAS CANCER; PERICARDIAL EFFUSION; PHARMACODYNAMICS; PNEUMONIA; PROTEINURIA; PRURITUS; RASH; REVIEW; SEX DIFFERENCE; SEX RATIO; SIDE EFFECT; SOFT TISSUE SARCOMA; SOLID TUMOR; STATISTICAL ANALYSIS; STOMATITIS; STROKE; THROMBOEMBOLISM; THROMBOSIS; TREATMENT RESPONSE; VEIN THROMBOSIS; WOUND HEALING IMPAIRMENT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DISEASE-FREE SURVIVAL; HUMANS; NEOPLASMS; RECOMBINANT PROTEINS; SURVIVAL RATE;

EID: 33845961014     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.11.015     Document Type: Review

References (103)

1. Gerber H.P., and Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65 (2005) 671-680
2. Zondor S.D., and Medina P.J. Bevacizumab: An angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann Pharmacother 38 (2004) 1258-1264
3. Hicklin D.J., and Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23 (2005) 1011-1027
4. Rosen L.S. Clinical experience with angiogenesis signaling inhibitors: Focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control 9 Suppl 2 (2002) 36-44
5. Herbst R.S., Onn A., and Sandler A. Angiogenesis and lung cancer: Prognostic and therapeutic implications. J Clin Oncol 23 (2005) 3243-3256
6. [published correction appears in Am J Health Syst Pharm. 2005;62:1241 ]. Mod S. Bevacizumab in combination chemotherapy forcolorectal and othercancers. Am J Health Syst Pharm 62 (2005) 1021-1032
7. Midgley R., and Kerr D. Bevacizumab-current status and future directions. Ann Oncol 16 (2005) 999-1004
8. Akagi Y., Liu W., Zebrowski B., et al. Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I. Cancer Res 58 (1998) 4008-4014
9. Nasu R., Kimura H., Akagi K., et al. Blood flow influences vascular growth during tumour angiogenesis. Br J Cancer 79 (1999) 780-786
10. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 333 (1995) 1757-1763
11. Gasparini G., Longo R., Fanelli M., and Teicher B.A. Combination of antiangiogenic therapy with other anticancer therapies: Results, challenges, and open questions. J Clin Oncol 23 (2005) 1295-1311
12. Kabbinavar F.F., Hambleton J., Mass R.D., et al. Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23 (2005) 3706-3712
13. Rosen L.S. VEGF-targeted therapy: Therapeutic potential and recent advances. Oncologist 10 (2005) 382-391
14. Augustin H.G. Translating angiogenesis research into the clinic: The challenges ahead. Br J Radiol 76 (2003) S3-S10
15. (bevacizumab) [package insert]. Avastin (2004), Genentech, South San Francisco, Calif
16. Wang Y., Fei D., Vanderlaan M., and Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 7 (2004) 335-345
17. Kabbinavar F.F., Schulz J., McCleod M., et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results ofa randomized phase II trial. J Clin Oncol 23 (2005) 3697-3705
18. Jain R.K. Normalizing tumorvasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 7 (2001) 987-989
19. Approval package for: Application number STN-125085/0. Review and evaluation of pharmacology data (August 15, 2006). http://www.fda.gov/cder/foi/nda/2004/STN
20. Melnyk O., Zimmerman M., Kim K.J., and Shuman M. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model. J Urol 161 (1999) 960-963
21. Mesiano S., Ferrara N., and Jaffe R.B. Role ofvascular endothelial growth factor in ovarian cancer: Inhibition of ascites formation by immunoneutralization. Am J Pathol 153 (1998) 1249-1256
22. Chen H.X. Expanding the clinical development of bevacizumab. Oncologist 9 Suppl 1 (2004) 27-35
23. Borgstrom P., Gold D.P., Hillan K.J., Ferrara N., et al. Importance of VEGF for breast cancer angiogenesis in vivo: Implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res 19 (1999) 4203-4214
24. Brower V. Evidence of efficacy: Researchers investigating markers for angiogenesis inhi bitors. J Natl Cancer Inst 95 (2003) 1425-1427
25. Jubb A.M., Hurwitz H.I., Bai W., et al. Impact of vascular endothelial growth factor-A expression, thrombospondin 2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 24 (2006) 217-227
26. Nguyen M. Angiogenic factors as tumor markers. Invest New Drugs 15 (1997) 29-37
27. Miller K.D., Chap L.I., Holmes F.A., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23 (2005) 792-799
28. Chicago, III. Abstract 766. Hillan K.J., Koeppen W., Tobin P., et al. The role of VEGF expression in response to bevacizumab plus capecitabine in metastatic breast cancer (MBC). Presented at: American Society of Clinical Oncology Annual Meeting (May 31-June 3, 2003)
29. Atlanta, Ga. Abstract 7027. Dowlati A., Gray R., Johnson D.H., et al. Prospective correlative assessment of biomarkers in E4599 randomized phase II/III trial of carboplatin and paclitaxel ± bevacizumab in advanced non-small cell lung cancer (NSCLC). Presented at: American Society of Clinical OncologyAnnual Meeting (June 2-6, 2006)
30. Gordon M.S., Margolin K., Talpaz M., et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 19 (2001) 843-850
31. Lin Y.S., Nguyen C., Mendoza J.L., et al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribu tion of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther. 288 (1999) 371-378
32. Accessed. Application number STN-125085/0. Clinical pharmacology/toxicology review (August 15, 2006). http://www.fda.gov/cder/foi/nda/2004/STN Accessed
33. Atlanta, Ga. Abstract 3540. Schueller J., Czejka M., Kiss A., et al. Influence of bevacizumab on the plasma disposition of CPT 11 and its metabolites in advanced colorectal cancer patients. Presented at: American Society of Clinical Oncology Annual Meeting (June 2-6, 2006)
34. Weiss K.D. Director, Office of Drug Evaluation VI, Office of New Drugs, CIDER. Letter from (February 26, 2004), Genentech, Inc. http://www.fda.gov/cder/foi/appletter/2004/1250851tr.pdf Accessed August 15, 2006
35. Park J.O., Lee S.I., Song S.Y., et al. Measuring response in solid tumors: Comparison of RECIST and WHO re sponse criteria. Jpn J Clin Oncol. 33 (2003) 533-537
36. Therasse P., Arbuck S.G., Eisenhauer E.A., et al., European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, and the National Cancer Institute of Canada. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 92 (2000) 205-216
37. de Gramont A., Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 18 (2000) 2938-2947
38. [published correction appears in Lancet. 2000;355:1372]. Douillard J.Y., Cunningham D., Roth A.D., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355 (2000) 1041-1047
39. Goldberg R.M., and Gill S. Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancer. Cancer Chemother Pharmacol. 54 Suppl 1 (2004) S57-S64
40. Saltz L.B., Cox J.V., Blanke C., et al., Irinotecan Study Group. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 343 (2000) 905-914
41. Grothey A., Sargent D., Goldberg R.M., and Schmoll H.J. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracilleucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 22 (2004) 1209-1214
42. Meyerhardt J.A., and Mayer R.J. Systemic therapy for colorectal cancer. N Engl J Med. 352 (2005) 476-487
43. Venook A. Critical evaluation of current treatments in metastatic colorectal cancer. Oncologist 10 (2005) 250-261
44. Tournigand C., Andre T., Achille E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol. 22 (2004) 229-237
45. Fernando N.H., and Hurwitz H.I. Targeted therapy of colorectal cancer: Clinical experience with bevacizumab. Oncologist 9 Suppl 1 (2004) 11-18
46. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group in Cancer. Clin Oncol. 16 (1998) 301-308
47. Kelly H., and Goldberg R.M. Systemic therapy for metastatic colorectal cancer: Current options, current evidence. J Clin Oncol. 23 (2005) 4553-4560
48. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 350 (2004) 2335-2342
49. Hurwitz H.I., Fehrenbacker L., Hainsworth J.D., et al. Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for firstline metastatic colorectal cancer. J Clin Oncol. 23 (2005) 3502-3508
50. Kabbinavar F., Hurwitz H.I., Fehrenbacher L., et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 21 (2003) 60-65
51. [published correction appears in J Clin Oncol. 1990;8:185]. Petrelli N., Douglass Jr. H.O., Herrera L., et al., Gastrointestinal Tumor Study Group. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial. J Clin Oncol. 7 (1989) 1419-1426
52. Orlando, Fla. Abstract 2. Giantonio B.J., Catalano P.J., Meropol N.J., et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Presented at: American Society of Clinical Oncology Annual Meeting (May 13-17, 2005)
53. Orlando, Fla. Abstract 3515. Hochster S., Welles L., Hart L., et al. Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/ fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cencer (mCRC): TREE 1 & 2 Studies. Presented at: American Society of Clinical Oncology Annual Meeting (May 13-17, 2005)
54. Hollywood, Fla. Abstract 241. Hochster S., Welles L., Hart L., et al. Bevacizumab (B) with oxaliplatin (O)based chemotherapy in the first-line therapy of metastatic colorectal cancer (mCRC): Preliminary results of the randomized "TREE-2" trial. Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium (January 27-29, 2005)
55. Atlanta, Ga. Abstract 3510. Hochster S.H., Hart L.L., Ramanathan R.K., et al. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis ofthe TREE-Study. Presented at: American Society of Clinical Oncology Annual Meeting (June 2-6, 2006)
56. San Francisco, Calif. Abstract 238. Spigel D.R., Hainsworth J.D., Burris H.A., et al. Phase II study of FOLFOX4, bevacizumab, and erlotinib as first-line therapy in patients with advanced colorectal cancer. Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium (January 26-28, 2006)
57. Hollywood, Fla. Abstract 289. Fernando N.H., Hurwitz H., Yu D., et al. A phase II study of oxaliplatin, capecitabine and bevacizumab in the treatment of metastatic colorectal cancer. Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium (January 27-29, 2005)
58. Orlando, Fla. Abstract 3508. Saltz L.B., Lenz H.J., Hochster H., et al. Randomized phase II trial of cetuximab/ bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Presented at: American Society of Clinical Oncology Annual Meeting (May 13-17, 2005)
59. Diaz-Rubio E. New chemotherapeutic advances in pancreatic, colorectal, and gastric cancers. Oncologist 9 (2004) 282-294
60. Atlanta, Ga. Abstract 3536. Hedrick E., Kozloff M., Hainsworth J., et al. Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the U.S. (BRiTE). Presented at: American Society of Clinical Oncology Annual Meeting (June 2-6, 2006)
61. Atlanta, Ga. Abstract 247. Kozloff M., Cohn A., Christiansen N., et al. Efficacy of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE). Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium (January 26-28, 2006)
62. Schneider B.P., and Miller K.D. Angiogenesis of breast cancer. J Clin Oncol. 23 (2005) 1782-1790
63. San Antonio, Tex. Abstract 446. Burstein H.J., Parker L.M., Savoie J., et al. Phase II trial of anti-VEGFantibody bevacizumab in combination with vi norelbine for refractory advanced breast cancer. Presented at: 25th Annual San Antonio Breast Cancer Symposium (December 11-14, 2002)
64. San Antonio, Tex. Abstract 224. Ramaswamy B., Rhoades C.A., Kendra K., et al. CTEP-sponsored phase II trial of bevacizumab (Avastin) in combi nation with docetaxel (Taxotere) in metastatic breast cancer. Presented at: 26th Annual San Antonio Breast Cancer Symposium (December 3-6, 2003)
65. Cobleigh M.A., Langmuir V.K., Sledge G.W., et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Sernin Oncol 30 Suppl 16 (2003) 117-124
66. Orlando, Fla. Virtual slide presentation. Miller K.D., Wang M., Gralow J., et al. E2100: A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer. Presented at: American Society of Clinical Oncology Annual Meeting (May 13-17, 2005)
67. Brady M.J., Cella D.F., Mo F., et al. Reliability and validity of the Functional Assessment ofCancer Therapy Breast quality-of-life instrument. J Clin Oncol. 15 (1997) 974-986
68. Rugo H.S. Bevacizumab in the treatment of breast cancer: Rationale and current data. Oncologist 9 Suppl 1 (2004) 43-49
69. San Antonio, Tex. Abstract 2088. Overmoyer B., Silverman P., Leeming R., et al. Phase II trial of neoadjuvant docetaxel with or without bevacizumab in patients with locally advanced breast cancer. Presented at: San Antonio Breast Cancer Symposium (December 8-11, 2004)
70. Herbst R.S., and Sandler A.B. Non-small cell lung cancer and antiangiogenic therapy: What can be expected of bevacizumab?. Oncologist 9 Suppl 1 (2004) 19-26
71. Ushijima C., Tsukamoto S., Yamazaki K., et al. High vascularity in the peripheral region of non-small cell lung can cer tissue is associated with tumor progression. Lung Cancer 34 (2001) 233-241
72. Passalidou E., Trivella M., Singh N., et al. Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas. Br J Cancer. 86 (2002) 244-249
73. Di Maio M., Gridelli C., Gallo C., et al. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: A pooled analysis of three randomised trials. Lancet Oncol. 6 (2005) 669-677
74. Sobrero A., and Bruzzi P. Bevacizumab plus fluorouracil: The value of being part of a developing story. J Clin Oncol. 23 (2005) 3660-3662
75. Herbst R.S., Johnson D.H., Mininberg E., et al. Phase I/II trial evaluating the anti-vascular endothelial growth fac tor monoclonal antibody bevacizumab in combination with the HER-1/ epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol. 23 (2005) 2544-2555
76. Johnson D.H., Fehrenbacher L., Novotny W.F., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 22 (2004) 2184-2191
77. Orlando, Fla. Abstract 4. Sandler A., Gray R., Brahmer A., et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC#704865) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial-E4599. Presented at: American Society of Clinical Oncology Annual Meeting (May 13-17, 2005)
78. Hainsworth J.D., Sosman J.A., Spigel D.R., et al. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 23 (2005) 7889-7896
79. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 349 (2003) 427-434
80. van Spronsen D.J., de Weijer K.J., Mulders P.F., and De Mulder P.H. Novel treatment strategies in clear-cell metastatic renal cell carcinoma. Anticancer Drugs 16 (2005) 709-717
81. Turner K.J., Moore J.W., Jones A., et al. Expression of hypoxia-inducible factors in human renal cancer: Relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res. 62 (2002) 2957-2961
82. New Orleans, La. Abstract 3050. Beeram M., Rowinsky E.K., Weiss G.R., et al. Durable disease stabilization and antitumor activity with OSI-774 in renal cell carcinoma (RCC). Presented at: American Society of Clinical OncologyAnnual Meeting (June 5-8, 2004)
83. Atlanta, Ga. Abstract 4523. Bukowski R.M., Kabbinavar F., Figlin R.A., et al. Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC). Presented at: American Society of Clinical Oncology Annual Meeting (June 2-6, 2006)
84. Jemal A., Tiwari R.C., Murray T., et al., American Cancer Society. Cancer statistics, 2004. CA Cancer J Clin 54 (2004) 8-29
85. Kindler H.L., Friberg G., Singh D.A., et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 23 (2005) 8033-8040
86. Itakura J., Ishiwata T., Shen B., et al. Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int J Cancer. 85 (2000) 27-34
87. Baker C.H., Solorzano C.C., and Fidler I.J. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res. 62 (2002) 1996-2003
88. Bruns C.J., Shrader M., Harbison M.T., et al. Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice. Int J Cancer. 102 (2002) 101-108
89. Burris III H.A., Moore M.J., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol. 15 (1997) 2403-2413
90. D'Adamo D.R., Anderson S.E., Albritton K., et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol. 23 (2005) 7135-7142
91. Chicago, III. Abstract 1578. Picus J., Halabi S., Rini B., et al. The use of bevacizumab (B) with docetaxel (D) and extramustine (E) in hormone refractory prostate cancer (HRPC): Initial results of CALGB 90006. Presented at: American Society of Clinical Oncology Annual Meeting (May 31-June 3, 2003)
92. Orlando, Fla. Abstract 4120. Zhu A.X., Sahani D., Norden-Zfoni A., et al. A phase II study ofgemcitabine, oxaliplatin in combination with be vacizumab (GEMOX-B) in patients with hepatocellular carcinoma. Presented at: American Society of Clinical Oncology Annual Meeting (May 13-17, 2005)
93. Santoro A., Tursz T., Mouridsen H., et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first line treatment of advanced soft tissue sarcomas: A randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 13 (1995) 1537-1545
94. Giles F.J. The vascular endothelial growth factor (VEGF) signaling pathway: A therapeutic target in patients with hematologic malignancies. Oncologist 6 Suppl 5 (2001) 32-39
95. Sane D.C., Anton L., and Brosnihan K.B. Angiogenic growth factors and hypertension. Angiogenesis 7 (2004) 193-201
96. Atlanta, Ga. Abstract 13539. Pande A.U., Lombardo J.C., Fakih M., et al. Bevacizumab (BV) induced hypertension (HT): A manageable toxicity. Presented at: American Society of Clinical Oncology Annual Meeting (June 2-6, 2006)
97. BLA STN #125085. Review and evaluation of toxicology data. Bevacizumab (AVASTIN) (August 15, 2006), Genetech, Inc., South San Francisco, CA. http://www.fda.gov/cder/foi/nda/2004/STN
98. 165 mediates glomerular endothelial repair. J Clin Invest. 104 (1999) 913-923
99. Ratner M. Genentech discloses safety concerns over Avastin. Nat Biotechnol. 22 (2004) 1198
100. Rowinsky E.K., Schwartz G.H., Gollob J.A., et al. Safety, pharmacokinetics, and activity ofABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol. 22 (2004) 3003-3015
101. Atlanta, Ga. Abstract 3542. Saltz L.B., Chung K.Y., Timoney J., et al. Simplification of bevacizumab (bev) administration: Do we need 90, 60, or even 30 minute infusion times?. Presented at: American Society of Clinical Oncology Annual Meeting (June 2-6, 2006)
102. Berenson A. A cancer drug shows promise, at a price that many can't pay. New York Times A1 (February 15, 2006) C2
103. Mayer R.J. Two steps forward in the treatment of colorectal cancer. N Engl J Med. 350 (2004) 2406-2408